Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  GRETAI SECURITIES MARKET  >  Tci    8436   TW0008436007

TCI

(8436)
  Report  
End-of-day quote. End-of-day quote GRETAI SECURITIES MARKET - 08/15
328 TWD   +0.92%
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Researchers Submit Patent Application, “Fermentation Product Of Punica Granatum And Uses Thereof”, for Approval (USPTO 20190224259): TCI Co. Ltd.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/14/2019 | 04:41pm EDT

2019 AUG 14 (NewsRx) -- By a News Reporter-Staff News Editor at Taiwan Daily Report -- From Washington, D.C., NewsRx journalists report that a patent application by the inventors Lin, Yung-Hsiang (Taipei, Taiwan); Chuang, Wei Hsiu (Taipei, Taiwan), filed on November 30, 2018, was made available online on July 25, 2019.

The patent’s assignee is TCI Co. Ltd. (Taipei, Taiwan).

News editors obtained the following quote from the background information supplied by the inventors: “The present invention relates to a fermentation product of Punica granatum and methods for regulating expression of MMP gene, TIMP gene and COL4A4 gene, promoting collagen production, and anti-aging by using the fermentation product of Punica granatum.

“Skin tissue is composed of epidermis, dermis and subcutaneous tissue. The dermis contains a large amount of collagen and hyaluronic acid, which is closely related to the water retention and elasticity of the skin. There is aging, rough skin or wrinkles in the human skin due to age, physiological factors or environmental factors. For example, the skin of normal young people has certain elasticity and tension. After the muscle of expression is relaxed, the skin will quickly recover, causing the wrinkles to disappear. But after the middle age, the skin begins to age significantly, the skin becomes thinner, harder, drier, and the tension is reduced. Reduced dermal collagen, elastic fiber degeneration and fracture reduce the tension and elasticity of the skin. Therefore, after the muscle of expression is relaxed, the skin cannot quickly recover, and the wrinkles are formed over time. As the age increases, the skin and subcutaneous tissue are more relaxed, and the atrophy or loss of the facial supporting tissue, as well as the muscles are soft, the skin will fall under the action of gravity, forming serious wrinkles. Rough skin is caused by external factors such as dryness, ultraviolet rays, detergents or chemicals, and internal factors such as disorders of hormone balance, and accompanied by the decrease of the barrier function of the stratum corneum, the decrease of the water content of the stratum corneum, hypermetabolic turnover of epidermis, the generation of scales and the roughening of the keratin. Therefore, if the cells on the skin lose their elasticity and moisturizing function, they may cause wrinkles, dryness and loss of luster on the skin.

“At present, the methods commonly used to solve skin problems are using pharmaceuticals, skin care products applied to the skin surface, or orally taking health foods with anti-aging effects. However, most of the conventional pharmaceuticals, skin care products and health foods are made of chemical ingredients. Long-term use is not only harmful to human health, but these products are often expensive and not affordable to the users.

“In order to solve the above problems, those skilled in the art urgently need to develop novel pharmaceuticals, skin care products or food products having the effects on promoting collagen production and anti-aging for the benefit of a large group of people in need thereof.”

As a supplement to the background information on this patent application, NewsRx correspondents also obtained the inventors’ summary information for this patent application: “A primary objective of the present invention is to provide a fermentation product of Punica granatum, obtained by a process comprising the following steps: (a) extracting the Punica granatum with water to obtain a Punica granatum extract; and (b) sequentially fermenting the Punica granatum extract with Saccharomyces cerevisiae and Lactobacillus plantarum to obtain a first fermentation product of Punica granatum; wherein the Saccharomyces cerevisiae has a concentration ranging from 0.01% to 0.5%, and the Lactobacillus plantarum has a concentration ranging from 0.01% to 0.25%.

“According to an embodiment of the present invention, a fermentation time of the Saccharomyces cerevisiae ranges from 1 to 2 days, and a fermentation time of the Lactobacillus plantarum ranges from 1 to 3 days.

“According to an embodiment of the present invention, the first fermentation product of Punica granatum is further fermented with Acetobacter aceti to obtain a second fermentation product of Punica granatum.

“According to an embodiment of the present invention, the Acetobacter aceti has a concentration ranging from 1% to 20%.

“According to an embodiment of the present invention, a fermentation time of the Acetobacter aceti ranges from 14 to 21 days.

“According to an embodiment of the present invention, an extraction temperature of the process ranges from 50.degree. C. to 100.degree. C., and an extraction time of the process ranges from 0.5 to 3 hours.

“Another objective of the present invention is to provide a method for regulating expression of matrix metalloproteinase (MMP) gene, tissue inhibitor of matrix metalloproteinase (TIMP) gene, and collagen type IV alpha 4 chain (COL4A4) gene, comprising administering to a subject in need thereof a composition comprising an effective amount of the aforesaid first fermentation product of Punica granatum.

“According to an embodiment of the present invention, the first fermentation product of Punica granatum is further fermented with Acetobacter aceti to obtain a second fermentation product of Punica granatum.

“According to an embodiment of the present invention, the composition is in the form of a pharmaceutical composition, a food product, or a cosmetic composition.

“According to an embodiment of the present invention, the MMP gene is MMP2 gene.

“According to an embodiment of the present invention, the TIMP gene is TIMP1 gene.

“Another objective of the present invention is to provide a method for promoting collagen production and anti-aging, comprising administering to a subject in need thereof a composition comprising an effective amount of the aforesaid first fermentation product of Punica granatum.

“According to an embodiment of the present invention, the composition is in the form of the cosmetic composition.

“According to an embodiment of the present invention, the first fermentation product of Punica granatum is further fermented with Acetobacter aceti to obtain a second fermentation product of Punica granatum.

“According to an embodiment of the present invention, the composition is in the form of the food product.

“In summary, the fermentation product of Punica granatum has the effect on regulating the expression of the MMP gene, the TIMP gene and the COL4A4 gene, releasing total polyphenols of the Punica granatum by the microbial fermentation process, increasing the antioxidant and skin care functions, promoting collagen production, reducing pigment production and accumulation, enhancing skin firmness, anti-aging and smoothing wrinkles.”

The claims supplied by the inventors are:

“1. A fermentation product of Punica granatum obtained by a process comprising the following steps: (a) extracting the Punica granatum with water to obtain a Punica granatum extract; and (b) sequentially fermenting the Punica granatum extract with Saccharomyces cerevisiae and Lactobacillus plantarum to obtain a first fermentation product of Punica granatum; wherein the Saccharomyces cerevisiae has a concentration ranging from 0.01% to 0.5%, and the Lactobacillus plantarum has a concentration ranging from 0.01% to 0.25%.

“2. The fermentation product of Punica granatum according to claim 1, wherein a fermentation time of the Saccharomyces cerevisiae ranges from 1 to 2 days, and a fermentation time of the Lactobacillus plantarum ranges from 1 to 3 days.

“3. The fermentation product of Punica granatum according to claim 1, wherein the first fermentation product of Punica granatum is further fermented with Acetobacter aceti to obtain a second fermentation product of Punica granatum.

“4. The fermentation product of Punica granatum according to claim 3, wherein the Acetobacter aceti has a concentration ranging from 1% to 20%.

“5. The fermentation product of Punica granatum according to claim 4, wherein a fermentation time of the Acetobacter aceti ranges from 14 to 21 days.

“6. The fermentation product of Punica granatum according to claim 1, wherein an extraction temperature of the process ranges from 50.degree. C. to 100.degree. C., and an extraction time of the process ranges from 0.5 to 3 hours.

“7. A method for regulating expression of matrix metalloproteinase (MMP) gene, tissue inhibitor of matrix metalloproteinase (TIMP) gene, and collagen type IV alpha 4 chain (COL4A4) gene, comprising administering to a subject in need thereof a composition comprising an effective amount of the first fermentation product of Punica granatum according to claim 1.

“8. The method according to claim 7, wherein the first fermentation product of Punica granatum is further fermented with Acetobacter aceti to obtain a second fermentation product of Punica granatum.

“9. The method according to claim 7, wherein the composition is in the form of a pharmaceutical composition, a food product, or a cosmetic composition.

“10. The method according to claim 7, wherein the MMP gene is MMP2 gene.

“11. The method according to claim 7, wherein the TIMP gene is TIMP1 gene.

“12. A method for promoting collagen production and anti-aging, comprising administering to a subject in need thereof a composition comprising an effective amount of the first fermentation product of Punica granatum according to claim 1.

“13. The method according to claim 12, wherein the composition is in the form of the cosmetic composition.

“14. The method according to claim 12, wherein the first fermentation product of Punica granatum is further fermented with Acetobacter aceti to obtain a second fermentation product of Punica granatum.

“15. The method according to claim 14, wherein the composition is in the form of the food product.”

For additional information on this patent application, see: Lin, Yung-Hsiang; Chuang, Wei Hsiu. Fermentation Product Of Punica Granatum And Uses Thereof. Filed November 30, 2018 and posted July 25, 2019. Patent URL: http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220190224259%22.PGNR.&OS=DN/20190224259&RS=DN/20190224259

(Our reports deliver fact-based news of research and discoveries from around the world.)

Copyright © 2019 NewsRx LLC, Taiwan Daily Report, source Geographic Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TCI

- No features available -

More news
Financials (TWD)
Sales 2019 10 572 M
EBIT 2019 2 751 M
Net income 2019 2 407 M
Finance 2019 3 934 M
Yield 2019 2,31%
P/E ratio 2019 16,3x
P/E ratio 2020 13,4x
EV / Sales2019 3,28x
EV / Sales2020 2,54x
Capitalization 38 602 M
Chart TCI
Duration : Period :
Tci Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 447,08  TWD
Last Close Price 327,00  TWD
Spread / Highest target 53,6%
Spread / Average Target 36,7%
Spread / Lowest Target 15,6%
EPS Revisions
Managers
NameTitle
Yung Hsiang Lin Chairman & General Manager
Cheng Hsien Chiang Head-Finance, Deputy Spokesman & IR Officer
Jui Hua Tsai Director
Shou Lu Chang Independent Director
Lung Yi Liao Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
TCI-37.28%1 236
NESTLÉ S.A.35.04%314 926
MONDELEZ INTERNATIONAL36.25%77 559
DANONE30.22%56 651
GENERAL MILLS39.52%32 788
THE HERSHEY COMPANY45.03%32 590